Clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia

Objective To evaluate the clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia. Methods The clinical efficacy for Mycoplasma pneumonia was analyzed in a randomized,controlled clinical trial of moxifloxacin compared with azithromycin plus ceftriaxone combination therapy in the treatment of community-acquired pneumonia. Results The efficacy rate was 96.4% in moxifloxacin group and 90.0% in the control group. Bacterial clearance rate in the two groups was 6/7 and 5/5,respectively. The difference between groups was not statistically significant (P0.05). The time to defervescence to 37.5 ℃ and hospital stay in moxifloxacin group [(3.2±1.5) d and (8.2±7.0) d] were shorter than those in the control group [(4.4±1.7) d and ( 10.0± 8.4 ) d](P0.05). The incidence of adverse drug reactions was 14.3% in moxifloxacin group and 26.7% in the control group. The difference was not statistically significant between the two groups (P0.05). Conclusions Efficacy of moxifloxacin monotherapy is equivalent to azithromycin plus ceftriaxone combination therapy in the treatment of Mycoplasma pneumonia. Moxifloxacin is better than the control therapy in terms of time to defervescence and hospital stay.